PD‐(L)1 inhibitorsvs. chemotherapyvs. their combination in front‐line treatment for NSCLC: An indirect comparison

We comprehensively compared the therapeutic effects and safety of PD‐1/L1 antibodies (I), chemotherapy (C) or their combination (I + C) as first‐line treatments for advanced NSCLC. Online databases were searched to identify RCTs. Survival outcomes and safety events were pooled by indirect treatment comparison. Main subgroup analyses were conducted according to PD‐L1 expression. A total of 11 RCTs involving 6,731 patients were included. Overall,...